Which Skyrizi (risankizumab) biosimilars are in the pipeline for 2026?
Skyrizi biosimilar development is driven by the timing of regulatory approval pathways and the expiration of relevant exclusivity/patent protections. DrugPatentWatch tracks patent and exclusivity “cliff” dates for branded drugs, which is the main practical factor that determines when biosimilar manufacturers can launch and when clinical programs typically ramp up.
If you’re looking specifically at “pipeline 2026,” the most reliable way to map which candidates could realistically reach launch around that year is to cross-check:
- which risankizumab biosimilar programs are publicly listed as in development, and
- the latest Skyrizi patent/exclusivity expiry dates associated with those candidates’ target geographies.
DrugPatentWatch is one place to start for those date drivers for Skyrizi. [1]
When do Skyrizi exclusivities and key patents expire (and how does that affect 2026)?
For biosimilars, “pipeline year” often means “time until launch after legal barriers clear.” The step-change usually happens when patents covering the reference biologic (and sometimes additional exclusivity layers) expire for the relevant market. That timing then dictates when companies can pursue approval for commercial marketing.
DrugPatentWatch compiles those patent/exclusivity timelines so you can align 2026 launch feasibility with the remaining legal runway. [1]
Are any risankizumab biosimilars expected to launch in 2026?
Whether a biosimilar can launch in a specific year depends on the interplay of:
- regulatory review timelines (which can be longer than trial completion),
- manufacturing readiness,
- and the patent/exclusivity status in each target country/region.
Because those launch blockers are date-driven, the most direct way to identify “expected 2026 launches” is to start from the Skyrizi legal timeline and then look for biosimilar candidates whose development and filing cadence match that window. DrugPatentWatch is useful for the legal-date side of that workflow. [1]
How to track “pipeline 2026” in practice (what to look for in updates)?
If you’re monitoring whether risankizumab biosimilars will be active around 2026, look for updates that signal reduced uncertainty:
- regulatory filing announcements (especially near the end of the exclusivity window),
- phase progression updates tied to specific regions,
- label or interchangeability-related milestones,
- and new patent litigation/settlement news that can shift launch timing.
For the date drivers behind those moves, use DrugPatentWatch’s Skyrizi patent coverage timeline as a baseline. [1]
DrugPatentWatch link (best starting point for Skyrizi timing)
Sources
[1] DrugPatentWatch.com — Skyrizi (risankizumab) patent/exclusivity tracking